AbbVie

Insider buying can be an encouraging signal for potential investors. Insiders were buying shares last week in the wake of earnings reports. Two big drugmakers saw sizable insider purchases in the past week. Conventional wisdom says that insiders and 10% owners really only buy shares of a company...

This weekend's Barron's cover story takes a look at whether the hot IPO market is a bubble. Other featured articles review Dividend Aristocrats on a roll and offer the results from a survey of tech CIOs. Also, the prospects for a pharmaceutical merger, a best-in-class cruise line operator...

This weekend's Barron's cover story looks at why pharmaceutical giants are making big bets on gene therapy. Other featured articles examine problems with packaged food companies and which high-yield dividends are safest. Also, the prospects for a weight-loss products leader and a fashion...

Benzinga has featured looks at many investor favorite stocks over the past week. Bullish calls included social media and cloud computing giants. Bearish calls included a crumbling conglomerate and a top drugmaker. Last week, the partial federal government shutdown ended, but just in time for a...

The cover story in this weekend's Barron's examines how blockchain technology is beginning to show promise. Other featured articles include income picks from top advisors and five standout dividend picks. Also, see the prospects for a trust and custodial bank and a leading telecom. "...

Benzinga has featured looks at many investor favorite stocks over the past week. Bullish calls included a leading big bank and an video streaming giant. Bearish calls included giants in tobacco and social media. The new earnings reporting season has gotten off to a strong start, offsetting the...

Insider buying can be an encouraging signal for potential investors. An activist investor took the next step in acquiring his target. Also, a couple of regular buyers returned to the buy windows this week. Conventional wisdom says that insiders and 10-percent owners really only buy shares of a...

Benzinga has featured looks at many investor favorite stocks over the past week. Bullish calls included a streaming video giant and a struggling social media player. Bearish calls included the iPhone maker and a leading pharmaceutical company. The Nasdaq ended May nearly 6 percent...

This weekend's Barron's cover story presents the findings of the latest Energy Roundtable. Other featured articles examine the prospects for a tech giant's quantum computing efforts and an industry leader with little to fear from Amazon. Also, Warren Buffett's latest annual...

Benzinga has featured a look at many investor favorite stocks over the past week. Bullish calls featured a top biotech, an online payment company and an energy infrastructure giant. Bearish calls included a leading coffee chain, REITs and a hotel operator in the news. Volatility came...

This weekend's Barron's cover story features the second part of the 2018 Barron's Roundtable feature. Each Roundtable panelist offers up a handful of recommendations and reasons why they like these particular picks now. Other featured articles include an investor's guide...

The preliminary success of a drug designed to combat idiopathic pulmonary fibrosis could give Galapagos NV (ADR) (NASDAQ: GLPG) a 10-percent boost, according to Morgan Stanley. A 23-person study of the drug GLPG1690, an autotaxin inhibitor, found that patients had better lung function than those...

Three leading biotech companies will step into the earnings spotlight this week. Consensus forecasts from Wall Street analysts call for earnings growth from just two of them. And only one of them has topped estimates by double-digits in recent quarters. While the biotechnology industry has had a...

The three largest biotechs are set to share their latest quarterly results this week. Wall Street analysts are looking for solid to strong growth from all three. However, expectations are lower for many other biotech and pharmaceutical companies reporting this week. The three largest public...

Two of the so-called FANG stocks offered up disappointing quarterly results last week. The other two FANG stocks are on deck to share their latest results this week. Wall Street analysts continue to look for strong earnings growth from both of them. The so-called FANG stocks were the momentum...